AU2022261908A1 - Mhc class ii t-cell modulatory polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof - Google Patents

Mhc class ii t-cell modulatory polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof Download PDF

Info

Publication number
AU2022261908A1
AU2022261908A1 AU2022261908A AU2022261908A AU2022261908A1 AU 2022261908 A1 AU2022261908 A1 AU 2022261908A1 AU 2022261908 A AU2022261908 A AU 2022261908A AU 2022261908 A AU2022261908 A AU 2022261908A AU 2022261908 A1 AU2022261908 A1 AU 2022261908A1
Authority
AU
Australia
Prior art keywords
polypeptide
amino acid
mhc class
tmp
chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022261908A
Other languages
English (en)
Inventor
Rodolfo J. Chaparro
Chee Meng Low
Ronald D. Seidel Iii
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cue Biopharma Inc
Original Assignee
Cue Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cue Biopharma Inc filed Critical Cue Biopharma Inc
Publication of AU2022261908A1 publication Critical patent/AU2022261908A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C12Y401/01015—Glutamate decarboxylase (4.1.1.15)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2022261908A 2021-04-21 2022-04-20 Mhc class ii t-cell modulatory polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof Pending AU2022261908A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163177641P 2021-04-21 2021-04-21
US63/177,641 2021-04-21
PCT/US2022/025547 WO2022226069A1 (en) 2021-04-21 2022-04-20 Mhc class ii t-cell modulatory polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof

Publications (1)

Publication Number Publication Date
AU2022261908A1 true AU2022261908A1 (en) 2023-10-05

Family

ID=83723127

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022261908A Pending AU2022261908A1 (en) 2021-04-21 2022-04-20 Mhc class ii t-cell modulatory polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof

Country Status (7)

Country Link
US (1) US20240101627A1 (enExample)
EP (1) EP4326754A4 (enExample)
JP (1) JP2024517658A (enExample)
CN (1) CN117337298A (enExample)
AU (1) AU2022261908A1 (enExample)
CA (1) CA3212762A1 (enExample)
WO (1) WO2022226069A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020534352A (ja) 2017-09-07 2020-11-26 キュー バイオファーマ，インコーポレーテッド コンジュゲーション部位を有するｔ細胞調節多量体ポリペプチド及びその使用方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107709356A (zh) * 2015-06-26 2018-02-16 南加利福尼亚大学 用于肿瘤特异性活化的掩蔽嵌合抗原受体t细胞
US20200231652A1 (en) * 2015-08-31 2020-07-23 National Research Council Of Canada Tgf-b-receptor ectodomain fusion molecules and uses thereof
WO2020132366A2 (en) * 2018-12-19 2020-06-25 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof
WO2020132365A2 (en) * 2018-12-19 2020-06-25 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof
EP3897690A4 (en) * 2018-12-19 2022-09-28 Cue Biopharma, Inc. T LYMPHOCYTE MODULATOR MULTIMERIC POLYPEPTIDES HAVING CONJUGATION SITES AND METHODS OF USE THEREOF
JP2022522405A (ja) * 2019-03-06 2022-04-19 キュー バイオファーマ， インコーポレイテッド Ｔ細胞調節多量体ポリペプチド及びその使用方法
EP3935079A4 (en) * 2019-03-06 2023-03-22 Cue Biopharma, Inc. T-CELL MODULATING ANTIGEN PRESENT POLYPEPTIDES AND METHODS OF USE THEREOF
WO2022226058A1 (en) * 2021-04-22 2022-10-27 Cue Biopharma, Inc. Antigen-presenting polypeptides with chemical conjugation sites and methods of use thereof

Also Published As

Publication number Publication date
EP4326754A1 (en) 2024-02-28
US20240101627A1 (en) 2024-03-28
CA3212762A1 (en) 2022-10-27
JP2024517658A (ja) 2024-04-23
CN117337298A (zh) 2024-01-02
WO2022226069A1 (en) 2022-10-27
EP4326754A4 (en) 2025-02-19

Similar Documents

Publication Publication Date Title
AU2022204946A1 (en) Molecules that selectively activate regulatory t cells for the treatment of autoimmune disease
AU2017210187B2 (en) Molecules that selectively activate regulatory T cells for the treatment of autoimmune diseases
US20240190933A1 (en) Antigen Presenting Polypeptide Complexes Bearing TGF-Beta and Methods of Use Thereof
US20240197846A1 (en) Antigen-Presenting Polypeptides with Chemical Conjugation Sites and Methods of Use Thereof
WO2021195108A1 (en) T cell modulatory polypeptides and methods of use thereof
WO2022099157A1 (en) Antigen presenting polypeptide complexes and methods of use thereof
US20240101627A1 (en) Mhc class ii t-cell modulatory polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof
US20240139298A1 (en) Mhc class ii t-cell modulatory polypeptides and methods of use thereof
US20230340054A1 (en) Interleukin-2 muteins and uses thereof
US20240270815A1 (en) Antigen Presenting Polypeptide Complexes and Methods of Use Thereof
US20240181025A1 (en) Antigen Presenting Polypeptide Complexes Bearing TGF-Beta and Methods of Use Thereof
WO2024006576A1 (en) Mhc class ii protein constructs